Generated by AI
BioAtla Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancers. BioAtla Inc. applies its proprietary conditionally active biologic platform to create monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates designed to become active in the tumor microenvironment while limiting activity in healthy tissues. Its current portfolio includes product candidates aimed at difficult-to-treat cancers such as non-small cell lung cancer, sarcoma, melanoma, and head and neck squamous cell carcinoma. The company’s work centers on advancing targeted oncology programs that are intended to improve selectivity and therapeutic precision in cancer treatment. Headquartered in San Diego, California, BioAtla Inc. operates as part of the biotechnology sector and remains focused on research, development, and clinical evaluation of its antibody therapeutics.
Website11085 Torreyana Road
San Diego, CA, 92121
United States
The latest articles about BCAB.
Detailed price information for Bioatla Inc (BCAB) from The Globe and Mail including charting and trades.
Find out all the key statistics for Bioatla Inc (BCAB), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Detailed price information for Bioatla Inc (BCAB) from The Globe and Mail including charting and trades.
Summary of Aug 28's posts. Generated by AI.
Summary of Dec 31's posts. Generated by AI.
Detailed price information for Bioatla Inc (BCAB) from The Globe and Mail including charting and trades.
Summary of Dec 31's posts. Generated by AI.
Summary of Aug 28's posts. Generated by AI.
Investors talking about BCAB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.